Last Updated: 16/07/2025
Safety, protective efficacy, and immunogenicity of FMP013/ALFQ in healthy malaria-naïve adults with CHMI
Objectives
The objective of this study is to measure the safety dosage and assess reactogenicity of candidate malaria vaccine FMP013/ALFQ.
United States Army Medical Research and Development Command (USAMRDC), United States
Walter Reed Army Institute of Research (WRAIR), United States
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability, and efficacy of Plasmodium falciparum Malaria Protein 013 (FMP013) combined with (ALF with QS-21), saponin molecule derived from the bark of Quillaja species (ALFQ) in healthy adult volunteers at different doses and dosing schedules.
Study type: Interventional
Enrollment: 46 participants
Primary purpose: Prevention
Allocation : Non-Randomized
Interventional Model: Parallel assignment
Masking: Open label
NCT number: NCT04268420
Phase: Phase I
Related Resources
